pp-021 Softgel capsules 100 mg
Dossier type
CTD
Dossier status
Under development
Country of origin
Canada
Comments
Indication: Dry AMD, prevention of dry-to-wet AMD conversion, wet AMD; Ph II; oral formulation, once-daily small-molecule systemic modulator with intraocular activity (anti-inflammatory/anti-oxidative/anti-angiogenic effect); crosses the blood-retina barrier; complementary to intravitreal therapies. VAP info: There is no approved oral therapy for AMD today; current standards are intravitreal injections.
Manufacturer #38499
The company is a pharmaceutical manufacturer operating within the biopharmaceutical and biotech sector, focused on research-driven activities related to the development of innovative pharmaceutical products, with operations centered on advancing therapeutic candidates and associated pharmaceutical products through structured preclinical and clinical development pathways for healthcare applications.